|
|
|
|
|
What to Expect from the Upcoming 2023 ASCO GU Cancers Symposium |
|
|
|
|
|
| Oral Abstract Session A - 8:00 - 9:30 AM PST
|
|
|
|
|
TALAPRO-2: Phase 3 Study of Talazoparib (TALA) + Enzalutamide (ENZA) Versus Placebo (PBO) + ENZA as First-Line (1L) Treatment in Patients (Pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Presented By: Neeraj Agarwal, MD
|
|
|
|
|
FORMULA-509: A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy (SRT) and 6 Months of GnRH Agonist with or Without Abiraterone Acetate/prednisone (AAP) and Apalutamide (Apa) Post-Radical Prostatectomy (RP).
Presented By: Paul L. Nguyen, MD
|
|
|
|
|
Patient-Level Data Meta-Analysis of a Multi-Modal Artificial Intelligence (MMAI) Prognostic Biomarker in High-Risk Prostate Cancer: Results from Six NRG/RTOG Phase III Randomized Trials
Presented By: Daniel Spratt, MD
|
|
|
|
|
| Advanced Prostate Cancer: New Targets, New Drugs, New Victories? 10:00 - 11:30 AM PST
|
|
|
|
|
Efficacy and Safety of Darolutamide (DARO) in Combination with Androgen-Deprivation Therapy (ADT) and Docetaxel (DOC) by Disease Volume and Disease Risk in the Phase 3 ARASENS Study
Presented By: Maha H. A. Hussain, MD, FASCO, FACP
Final Overall Survival (OS) in PROpel: Abiraterone (Abi) and Olaparib (Ola) Versus Abiraterone and Placebo (Pbo) as First-Line (1L) Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Presented By: Noel W. Clarke, FRCS
|
|
|
|
|
|
|
|
|
|
| Trials in Progress Poster Session A: Prostate Cancer - 11:30 AM PST |
|
|
|
|
AlphaBet: A Phase I/II Trial Evaluating the Combination of Radium-223 and [177Lu]Lu-PSMA-I&T in Patients (Pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Presented By: Arun Azad Ph.D., MBBS, FRACP
|
|
|
|
|
| Poster Session A: Prostate Cancer - 11:30 AM PST |
|
|
|
|
Randomized, Double-Blinded Phase II Study of Ketoconazole (Keto), Hydrocortisone (HC), and Anti-PSMA Antibody J591 Labeled with 177Lu or 111In in Patients (Pts) with High-Risk Non-Metastatic (Met) Castration-Resistant Prostate Cancer (M0 CRPC).
Presented By: Scott T. Tagawa, MD, MS, FACP
|
|
|
|
|
Circulating Tumor DNA Analysis of IMbassador250: Association of ctDNA Fraction, AR Alterations and Therapy Outcome in mCRPC
Presented By: Christopher Sweeney, MBBS
|
|
|
|
|
Geographic Variation in Utilization of Doublet Therapy for Metastatic Prostate Cancer
Presented By: Samuel L. Washington, MD
|
|
|
|
|
Time Interval Between Radium‑223 (223Ra) Therapy and Lutetium-177–prostate-Specific Membrane Antigen (177Lu-PSMA) Treatment and Outcomes in the RALU Study
Presented By: Kambiz Rahbar, MD
|
|
|
|
|
Real World (Rw) Racial Differences in Treatment (Tx) Patterns and Clinical Outcomes Among Patients (Pts) with mCRPC
Presented By: Pedro C. Barata, MD, MSc
|
|
|
|
|
A Phase 2 Randomized Open-Label Study of Oral Darolutamide Monotherapy vs. Androgen Deprivation Therapy in Men with Hormone-Naive Prostate Cancer (EORTC-GUCG 1532)
Presented By: Bertrand F. Tombal, Ph.D.
|
|
|
|
|
Oral EPI-7386 in Patients with Metastatic Castration-Resistant Prostate Cancer
Presented By: Russell Kent Pachynski, MD
|
|
|
|
|
Phase 1/2 Study of EPI-7386 in Combination with Enzalutamide (Enz) Compared with Enz Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Presented By: Andrew Leonard Laccetti, MD, MS
Baseline Characteristics Associated with PSA Progression-Free Survival in Patients (Pts) with High-Risk Biochemically Relapsed Prostate Cancer: Results from the Phase 3 PRESTO Study (AFT-19)
Presented By: Rahul Raj Aggarwal MD
|
|
|
|
|
|
|
|
| Rapid Abstract Session: Prostate Cancer - 4:45 - 5:45 PM PST
|
|
|
|
|
Randomized, Double-Blinded Phase II Study of Ketoconazole (Keto), Hydrocortisone (HC), and Anti-PSMA Antibody J591 Labeled with 177Lu or 111In in Patients (Pts) with High-Risk Non-Metastatic (Met) Castration-Resistant Prostate Cancer (M0 CRPC)
Presented By: Scott T. Tagawa, MD, MS, FACS
|
|
|
|
|
|
|
| Rapid Abstract Session: Urothelial Carcinoma - 7:00 AM - 8:00 AM PST |
|
|
|
|
Cell-Free Urinary Tumor DNA to Detect Minimal Residual Disease Prior to Repeat-Transurethral Resection of Bladder Tumor in Non–muscle-Invasive Bladder Cancer: A Prospective Study
Presented By: Kyle M. Rose, MD
|
|
|
|
|
Co-Primary Endpoint Analysis of HCRN GU 16-257: Phase 2 Trial of Gemcitabine, Cisplatin, plus Nivolumab with Selective Bladder Sparing in Patients with Muscle-Invasive Bladder Cancer (MIBC)
Presented By: Matt D. Galsky, MD, FASCO
|
|
|
|
|
HCRN GU14-188: Phase Ib/II Study of Neoadjuvant Pembrolizumab and Chemotherapy for T2-4aN0M0 Urothelial Cancer
Presented By: Jason Brown, MD, Ph.D.
|
|
|
|
|
Primary Analysis of TROPHY-U-01 Cohort 2, a Phase 2 Study of Sacituzumab Govitecan (SG) in Platinum (PT)-Ineligible Patients (Pts) with Metastatic Urothelial Cancer (mUC) That Progressed After Prior Checkpoint Inhibitor (CPI) Therapy
Presented By: Daniel P. Petrylak, MD
|
|
|
|
|
| Poster Session B: Prostate Cancer and Urothelial Carcinoma - 12:30 PM PST
|
|
|
|
|
The Impact of Blue Light Cystoscopy Use Among Patients with Non-Muscle Invasive Bladder Cancer in an Equal Access Setting
Presented By: Sanjay Das, MD
|
|
|
|
|
Radical Nephroureterectomy Followed by Adjuvant Chemotherapy (RNU-AC) Versus Observation (RNU-O) in Early-Stage Upper Urinary Tract Cancers with Variant Histology (UUTC-VH).
Presented By: Karan Jatwani, MD
|
|
|
|
|
Quality of Life in QUILT 3.032 Study: Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Receiving IL-15RαFc Superagonist N-803 plus BCG.
Presented By: Karim Chamie MD
|
|
|
|
|
Avelumab First-Line (1L) Maintenance for Advanced Urothelial Carcinoma (UC): Long-Term Follow-up from the JAVELIN Bladder 100 Trial in Subgroups Defined by 1L Chemotherapy Regimen and Analysis of Overall Survival (OS) from Start of 1L Chemotherapy.
Presented By: Srikala S. Sridhar, MD, MSc, FRCPC
|
|
|
|
|
| Oral Abstract Session B: Urothelial Carcinoma - 2:00 - 3:30 PM PST |
|
|
|
|
Atezolizumab (Atezo) + Platinum/gemcitabine (Plt/gem) vs Placebo + Plt/gem for First-Line (1L) Treatment (Tx) of Locally Advanced or Metastatic Urothelial Carcinoma (mUC): Final OS from the Randomized Phase 3 IMvigor130 Study
Presented By: Matt D. Galsky, MD, FASCO
|
|
|
|
|
|
|
| Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers - 7:00 AM PST
|
|
|
|
|
Overall Survival (OS) and Efficacy Results of Second-Line Treatment in Patients (Pts) with Metastatic Clear Cell Renal Cell Carcinoma (mRCC) Treated in the Randomized Phase II BIONIKK Trial
Presented By: Yann-Alexandre Vano, MD
Outcomes by IMDC Risk in the COSMIC-313 Phase 3 Trial Evaluating Cabozantinib (C) plus Nivolumab (N) and Ipilimumab (I) in First-Line Advanced RCC (aRCC) of IMDC Intermediate or Poor Risk
Presented By: Thomas Powles, MBBS, MRCP, MD
|
|
|
|
|
|
|
|
|
|
Treatment-Free Survival (TFS) Outcomes from the Phase II Study of Nivolumab and Salvage Nivolumab + Ipilimumab in Advanced Clear Cell Renal Cell Carcinoma (aRCC) (HCRN GU16-260-Cohort A).
Presented By: Michael B. Atkins, MD
|
|
|
|
|
| Oral Abstract Session C: Renal and Rare Tumors - 2:00 PM PST |
|
|
|
|
Results from Phase 3 Study of 89Zr-DFO-Girentuximab for PET/CT Imaging of Clear Cell Renal Cell Carcinoma (ZIRCON)
Presented By: Brian M. Shuch, MD
|
|
|
|
|
|
|
|
